The Gilead subsidiary company Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately-held biotechnology company developing in vivo CAR therapeutics, for $350 ...

Exorphia announced that it has signed a business collaboration agreement with fellow Japanese company Rohto Pharmaceutical, ...

UK and USA-listed PureTech Health has sought to show the strength of its position in idiopathic pulmonary fibrosis (IPF) at ...

Celldex Therapeutics shares fell as much as 13% on Wednesday, after it posted mixed top-line results from its ongoing Phase II study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic ...

German gene therapies developer VeonGen Therapeutics today revealed that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to VG801, its ...

France’s Nicox has announced that daily dosing of NCX 470 0.1%, a novel nitric oxide (NO)-donating bimatoprost eye drop, met ...

The UK’s NHS Business Services Authority's annual 'Prescribing for Diabetes - England 2015/16 to 2024/25' report reveals that diabetes treatments now account for 15% of all NHS prescription spending, ...

Danish allergy immunotherapy specialist ALK Abello today posted financial results which pleased investors, with its shares rising 6.2% to 199.50 kroner.

For what is reportedly the first time in decades, the American Academy of Pediatrics (AAP) has contradicted the US Centers for Disease Control and Prevention (CDC) over its recommended immunization ...

Ireland-headquartered Jazz Pharmaceuticals and Denmark’s Saniona have entered into a global license agreement for Jazz to obtain exclusive worldwide rights to develop SAN2355, a highly differentiated, ...

Australia’s Neurizon Therapeutics, a biotech advancing innovative treatments for neurodegenerative diseases, has reported positive top-line results from the Open-Label Extension (OLE) study of its ...

The UK’s National Institute for Health and Care Excellence (NICE) has today (August 21) recommended the use of Japanese pharma major Astellas’ enfortumab vedotin with MSD’s Keytruda (pembrolizumab) ...